Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Its news flow centers on the clinical and regulatory progress of its lead drug candidate, PrimeC, a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, in a fixed dose designed to target multiple disease mechanisms.
News updates for NRSN commonly cover milestones in ALS and Alzheimer’s clinical programs. These include Phase 2 and Phase 2b trial readouts, such as the PARADIGM study in ALS and the RoAD proof-of-concept study in Alzheimer’s disease, along with biomarker analyses that the company uses to interpret treatment effects. Press releases also highlight safety and tolerability findings, including reports of favorable safety profiles and absence of new or unexpected safety signals in clinical studies.
Investors and observers can expect coverage of regulatory interactions, such as FDA clearance to initiate a pivotal Phase 3 trial of PrimeC in ALS, database lock announcements for Alzheimer’s trials, and updates on planned submissions to agencies like Health Canada. Corporate and financing developments, including private placements of ordinary shares and business updates, are also frequent topics.
This news page aggregates these company-issued announcements, SEC-related communications and other public disclosures about NeuroSense’s progress. It is useful for readers who want to follow NRSN’s clinical trial milestones, biomarker-driven research updates, regulatory steps and capital-raising activities as the company advances PrimeC in ALS and Alzheimer’s disease.
NeuroSense (NASDAQ: NRSN) announced that Prof. Steven E. Arnold, a noted Alzheimer's expert and Professor of Neurology at Harvard Medical School, has joined its Scientific Advisory Board.
The company said Prof. Arnold brings biomarker-driven clinical development and translational neuroscience experience as NeuroSense advances its PrimeC programs in ALS and Alzheimer's disease. NeuroSense reported that its proof-of-concept Alzheimer's study (RoAD) showed a favorable safety and tolerability profile, and that clinical and biomarker outcomes from RoAD are expected in Q1 2026.
NeuroSense (NASDAQ: NRSN) reported completion of the safety analysis from its Phase 2 randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC in Alzheimer's disease on Dec 22, 2025.
The safety review found a favorable tolerability profile, with no serious adverse events reported and no new or unexpected safety signals identified. Clinical outcome measures in this exploratory proof-of-concept study are descriptive by design.
NeuroSense will analyze clinical observations together with biomarker data to aid interpretation, and full clinical and biomarker results are expected in Q1 2026.
NeuroSense (NASDAQ: NRSN) said it is resuming regulatory activity in Canada for PrimeC in amyotrophic lateral sclerosis (ALS) after a productive discussion with Health Canada.
Health Canada outlined remaining requirements and confirmed NeuroSense's proposed next steps align with the Agency's expectations. The company is preparing for a pre‑NDS meeting currently contemplated in April 2026. With additional clinical data recently generated and further analyses underway, NeuroSense said it anticipates a potential NDS submission by mid‑2026, pending a successful meeting and completion of final submission components.
NeuroSense will provide more details at an investor webinar on December 8, 2025.
NeuroSense (Nasdaq: NRSN) announced that the U.S. Food and Drug Administration completed review of its IND amendment and authorized initiation of the pivotal Phase 3 trial PARAGON evaluating PrimeC in amyotrophic lateral sclerosis (ALS) on Nov 24, 2025. PARAGON is planned as a global, double-blind, 12-month, placebo-controlled study with 300 participants randomized 2:1 (PrimeC:placebo), an open-label extension, an adaptive design with interim analyses, and is powered at >95% for its primary endpoint. NeuroSense aims to enroll the first patient in the coming months subject to securing strategic resources. Additional trial details and timelines will be presented at an investor webinar on Dec 8, 2025.
NeuroSense (NASDAQ: NRSN) will host an investor webinar on December 8, 2025 at 8:30 a.m. ET to provide business, regulatory and clinical updates.
Planned topics include the Phase 3 PARAGON study initiation (ALS), submission for Notice of Compliance with conditions (NOC/c) in Canada, the status of a binding term sheet executed in December 2024, and updates on the RoAD Phase 2 program (Alzheimer's disease). Investors can register to attend the webcast.
NeuroSense (NASDAQ: NRSN) reported Phase‑2b plasma biomarker results for PrimeC on October 6, 2025 showing statistically significant reductions in multiple Alzheimer's‑linked microRNAs. Key measured reductions from baseline include miR‑21‑5p (p=0.003), miR‑146a‑5p (p=0.007), miR‑let‑7e‑5p (p=0.006) and miR‑let‑7a‑5p (p=0.028), while placebo showed no significant changes over time. The company said these miRNA changes reflect reduced neuroinflammatory and neurodegenerative activity and support PrimeC's potential as a disease‑modifying therapy. NeuroSense indicated the data will inform design of a follow‑on Alzheimer's study and that Phase‑3 readiness for PrimeC in ALS remains ongoing.
NeuroSense Therapeutics (NASDAQ:NRSN) has reported positive initial results from its Phase 2 RoAD clinical trial of PrimeC for Alzheimer's disease. The study, conducted in collaboration with NeuroKaire, demonstrated that PrimeC enhanced neuroplasticity in patient-derived neurons while showing no treatment-related toxicity.
Using NeuroKaire's proprietary technology, which converts patient blood samples into brain cells, researchers observed improvements in brain-cell connectivity and health. The ongoing Phase 2 trial is a randomized, double-blind, placebo-controlled study evaluating PrimeC in mild-to-moderate Alzheimer's patients over 12 months.
NeuroSense Therapeutics (NASDAQ: NRSN), a late-clinical stage biotech company focused on neurodegenerative diseases, has secured a $500,000 private placement from a single investor. The company will issue 333,334 ordinary shares at $1.50 per share, representing a significant 40% premium to the September 3, 2025 closing price.
The financing, expected to close on September 8, 2025, will provide working capital and serve as a bridge to upcoming milestones. CEO Alon Ben-Noon highlighted this as their third premium-to-market financing, emphasizing minimal shareholder dilution while strengthening the company's balance sheet.
NeuroSense Therapeutics (NASDAQ: NRSN) provided a comprehensive business update for H1 2025, highlighting progress in its ALS treatment development. The company's lead candidate PrimeC showed promising Phase 2b results, with treatment slowing functional decline by ~40% and improving overall survival by 74% in the per-protocol population.
Key developments include regaining Nasdaq compliance through a $5M private placement, advancing manufacturing capabilities to commercial scale, and preparing for a Phase 3 trial in H2 2025. The company reported reduced R&D expenses of $2.5M (down 32.9% YoY) and maintained stable G&A expenses at $2.2M.
NeuroSense is pursuing regulatory pathways including a planned NOC/c submission in Canada and continues discussions for a potential global pharmaceutical partnership following a Q4 2024 binding term sheet.
NeuroSense Therapeutics (NASDAQ:NRSN) has announced an upcoming live webcast featuring CEO Alon Ben-Noon in conversation with award-winning actor and ALS advocate Aaron Lazar. The event, scheduled for August 4, 2025, at 2:00 PM EST, will focus on PrimeC, the company's investigational ALS therapy.
The interactive session will explore NeuroSense's regulatory progress in Canada, potential pharma partnerships, and the science behind PrimeC's development. Lazar, who was recently diagnosed with ALS, will lead the discussion while sharing his personal perspective on the disease. Participants will have the opportunity to engage through a live Q&A session.
FAQ
What is the current stock price of Neurosense Therapeutics (NRSN)?
What is the market cap of Neurosense Therapeutics (NRSN)?
